Evidence Table 160. KQ4—Continuous data—Absorption

| **Author Year****Study Design** | **Definition of outcome** | **CHD Risk Category** | **CVD drug (dose mg/d)** | **Supplement/ Control** | **N** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change / % change from baseline /****SD /****P Value** | **Between group differences in Means / medians****SD /****P Value** | **Additional comments**  | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ***Bioavailability (F)*** *– no outcome data* |  |  |  |  |  |  |  |  |  |  |